The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...
The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition ...
TipRanks on MSN
Crispr Therapeutics announces Phase 1 data for CTX310
CRISPR Therapeutics (CRSP) announced positive Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo ...
Please provide your email address to receive an email when new articles are posted on . AACE published its first updated guideline on the pharmacologic management of adults with dyslipidemia since ...
MedPage Today on MSN
Gene Therapy Shows Promise for Cutting LDL in Half in Tough-to-Treat Dyslipidemia
N EW ORLEANS – A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that ...
A new dyslipidemia guideline from the American Association of Clinical Endocrinology (AACE) offers evidence-based recommendations for the use of newer drugs and focuses on outcomes that are important ...
A meta-analysis reveals that oral Janus kinase inhibitors elevate LDL and HDL cholesterol, underscoring the need for lipid monitoring in patients receiving JAK inhibitor therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback